BioWorld-International-2011-01-26

LONDON – BioVex Group Inc. is to be acquired by Amgen Inc. in a cash sale that values the University College London spinout at up to $1 billion. There will be $425 million up front for the investors of the privately held cancer vaccines specialist, with $575 million in additional payments against regulatory and sales milestones.

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract